Is low dose of botulinum toxin effective in controlling chronic pain in sleep bruxism, awake bruxism, and temporomandibular disorder?

CRANIO® ◽  
2021 ◽  
pp. 1-8
Author(s):  
Maristela Corrêa de Lima ◽  
Célia Marisa Rizzatti Barbosa ◽  
Maria Beatriz Duarte Gavião ◽  
Paulo Henrique Ferreira Caria
Keyword(s):  
Chronic Pain ◽  
Botulinum Toxin ◽  
Low Dose ◽  
Temporomandibular Disorder ◽  
Sleep Bruxism ◽  
Awake Bruxism

scholarly journals Is dopaminergic medication dose associated with self-reported bruxism in Parkinson’s disease? A cross-sectional, questionnaire-based study

2020 ◽  
Author(s):  
M. C. Verhoeff ◽  
M. Koutris ◽  
M. K. A. van Selms ◽  
A. N. Brandwijk ◽  
M. S. Heres ◽  
...  
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Health Care Providers ◽  
Temporomandibular Disorder ◽  
Tooth Wear ◽  
Sleep Bruxism ◽  
Care Providers ◽  
Dopaminergic Medication ◽  
Medication Dose ◽  
Awake Bruxism

Abstract Objectives It is not clear whether dopaminergic medication influences bruxism behaviour in patients with Parkinson’s disease (PD). Therefore, the aims are to investigate (i) the prevalence of possible (i.e., self-reported) bruxism (sleep and awake) in PD patients, and (ii) whether the use of dopaminergic medication and other factors (viz., demographic characteristics, PD-related factors, and possible consequences of bruxism) are associated with possible bruxism (sleep or awake). Materials and methods This study concerns a secondary analysis of an earlier published study. Three hundred ninety-five PD patients (67.9 ± 8.6 years of age; 58.7% males) were included. The levodopa equivalent daily dosage (LEDD) was used as a measure of the dopaminergic medication level. Subsequently, a logistic regression analysis was performed for the dependent variables ‘awake bruxism’ and ‘sleep bruxism’, with the following predictors: gender, age, LEDD, time since PD diagnosis, temporomandibular disorder (TMD) pain, jaw locks, and tooth wear. Results The prevalence of possible awake and sleep bruxism was 46.0% and 24.3%, respectively. Awake bruxism was associated with sleep bruxism (OR = 8.52; 95% CI 3.56–20.40), TMD pain (OR = 4.51; 95% CI 2.31–8.79), and tooth wear (OR = 1.87; 95% CI 1.02–3.43). Sleep bruxism was associated with tooth wear (OR = 12.49; 95% CI 4.97–31.38) and awake bruxism (OR = 9.48; 95% CI 4.24–21.19). Dopaminergic medication dose was not associated with awake bruxism (OR = 1.0; 95% CI 0.99–1.00) or sleep bruxism (OR = 1.0; 95% CI 0.99–1.00). Conclusion Bruxism is a common condition in PD patients, but is not associated with the dopaminergic medication dose. Clinical relevance (Oral) health care providers should be alerted about the possibility of sleep and awake bruxism activity in PD patients, along with this activity’s possible negative health outcomes (viz., TMD pain, tooth wear).

scholarly journals Low Dose Ketamine Infusion for Comorbid Posttraumatic Stress Disorder and Chronic Pain: A Randomized Double-Blind Clinical Trial

2020 ◽  
Vol 4 ◽  
pp. 247054702098167
Author(s):  
Alisher R. Dadabayev ◽  
Sonalee A. Joshi ◽  
Mariam H. Reda ◽  
Tamar Lake ◽  
Mark S. Hausman ◽  
...  
Keyword(s):  
Posttraumatic Stress Disorder ◽  
Chronic Pain ◽  
Posttraumatic Stress ◽  
Outcome Measures ◽  
Low Dose ◽  
Stress Disorder ◽  
Double Blind ◽  
Impact Of Event Scale ◽  
Event Scale ◽  
Ketamine Infusion

Objective To date, treatment options (i.e. psychotherapy, antidepressant medications) for patients with posttraumatic stress disorder (PTSD), are relatively few, and considering their limited efficacy, novel therapies have gained interest among researchers and treatment providers alike. Among patients with chronic pain (CP) about one third experience comorbid PTSD, which further complicates their already challenging pharmacological regimens. Low dose ketamine infusion has shown promise in PTSD, and in treatment of CP, however they have not been studied in comorbid population and under rigorous control conditions. Methods We compared the effects of a single dose of either ketamine (0.5 mg/kg) or ketorolac (15 mg) over a 40-minute of IV infusion in CP patients with and without PTSD, in double blind, randomized study. Measures were collected before, during, one day and seven days after the infusion. A planned sample size of 40 patients randomly assigned to treatment order was estimated to provide 80% power to detect a hypothesized treatment difference after the infusion. Main Outcome and Measures: The primary outcome measures were change in PTSD symptom severity assessed with the Impact of Event Scale–Revised (IES-R) and Visual Analogue Scale (VAS) for pain administered by a study clinician 24 hours post infusion. Secondary outcome measures included Impact of Event Scale–Revised (IES-R), VAS and Brief Pain Inventory (Short Form) for pain 1 week after the infusion. Results Both treatments offered comparable improvement of PTSD and CP symptoms that persisted for 7 days after the infusion. Patients with comorbid PTSD and CP experienced less dissociative side effects compared to the CP group. Surprisingly, ketorolac infusion resulted in dissociative symptoms in CP patients only. Conclusions This first prospective study comparing effects of subanesthetic ketamine versus ketorolac infusions for comorbid PTSD and CP, suggests that both ketamine and ketorolac might offer meaningful and durable response for both PTSD and CP symptoms.

F522 LOW DOSE INTRAVENOUS KETAMINE FOR POST CARDIAC SURGERY PAIN: DOES IT HELP DECREASE THE INCIDENCE OF CHRONIC PAIN?

2011 ◽  
Vol 5 (S1) ◽  
pp. 165-165
Author(s):  
G. Lalumière ◽  
J. Cogan ◽  
G. Vargas-Schafer ◽  
Z. Yegin ◽  
A. Rochon ◽  
...  
Keyword(s):  
Chronic Pain ◽  
Cardiac Surgery ◽  
Low Dose ◽  
Intravenous Ketamine ◽  
Post Cardiac Surgery

scholarly journals Botulinum Toxin A Treatment for Chronic Pain in Cerebral Palsy Patients

2007 ◽  
Vol 44 (7) ◽  
pp. 398-401
Author(s):  
Makoto RYU ◽  
Hideaki KUBOTA ◽  
Yutaka OKETANI ◽  
Yumi ITO ◽  
Hiromichi HARA
Keyword(s):  
Chronic Pain ◽  
Cerebral Palsy ◽  
Botulinum Toxin ◽  
Botulinum Toxin A ◽  
Toxin A

Acute and Chronic Temporomandibular Disorder Pain: A critical review of differentiating factors and predictors of acute to chronic pain transition

2021 ◽  
Author(s):  
Omar Sabsoob ◽  
Sherif M. Elsaraj ◽  
Mervyn Gornitsky ◽  
Elise Laszlo ◽  
James R. Fricton ◽  
...  
Keyword(s):  
Chronic Pain ◽  
Critical Review ◽  
Temporomandibular Disorder

scholarly journals Therapeutic use of botulinum toxin in pain treatment

2018 ◽  
Vol 2 (3) ◽  
Author(s):  
Raj Kumar
Keyword(s):  
Chronic Pain ◽  
Nervous System ◽  
Botulinum Toxin ◽  
Acetylcholine Release ◽  
Pain Treatment ◽  
Muscle Relaxation ◽  
Cholinergic Synapse ◽  
Systems Research ◽  
Release Of Acetylcholine ◽  
Myofascial Syndrome

Botulinum toxin is one of the most potent molecule known to mankind. A neurotoxin, with high affinity for cholinergic synapse, is effectively capable of inhibiting the release of acetylcholine. On the other hand, botulinum toxin is therapeutically used for several musculoskeletal disorders. Although most of the therapeutic effect of botulinum toxin is due to temporary skeletal muscle relaxation (mainly due to inhibition of the acetylcholine release), other effects on the nervous system are also investigated. One of the therapeutically investigated areas of the botulinum neurotoxin (BoNT) is the treatment of pain. At present, it is used for several chronic pain diseases, such as myofascial syndrome, headaches, arthritis, and neuropathic pain. Although the effect of botulinum toxin in pain is mainly due to its effect on cholinergic transmission in the somatic and autonomic nervous systems, research suggests that botulinum toxin can also provide benefits related to effects on cholinergic control of cholinergic nociceptive and antinociceptive systems. Furthermore, evidence suggests that botulinum toxin can also affect central nervous system (CNS). In summary, botulinum toxin holds great potential for pain treatments. It may be also useful for the pain treatments where other methods are ineffective with no side effect(s). Further studies will establish the exact analgesic mechanisms, efficacy, and complication of botulinum toxin in chronic pain disorders, and to some extent acute pain disorders.

Low Dose Amitriptyline in Chronic Pain

1991 ◽  
Vol XXXV (6) ◽  
pp. 349
Author(s):  
F. G. ZITMAN ◽  
A. C. G. LINSSEN ◽  
P. M. EDELBROEK ◽  
T. STIJNEN
Keyword(s):  
Chronic Pain ◽  
Low Dose

scholarly journals The Epidemiology of Bruxism in Relation to Psychological Factors

2022 ◽  
Vol 19 (2) ◽  
pp. 691
Author(s):  
Mirela Ioana Flueraşu ◽  
Ioana Corina Bocşan ◽  
Ioan-Andrei Țig ◽  
Simona Maria Iacob ◽  
Daniela Popa ◽  
...  
Keyword(s):  
Prospective Study ◽  
Muscle Activity ◽  
Psychological Factors ◽  
Sleep Bruxism ◽  
Cross Sectional ◽  
Female Sex ◽  
Anonymous Questionnaire ◽  
Observational Cohort ◽  
High Degree ◽  
Awake Bruxism

The aim of the present study was to establish the prevalence of sleep/awake bruxism among young students in Transylvania and to correlate the presence of this muscle activity with behavioral variations. This analytical, observational, cohort, cross-sectional, and prospective study involved 308 volunteers aged between 19 and 30 years of different nationalities, all students of the “Iuliu Hațieganu” University of Medicine and Pharmacy in Cluj-Napoca, Romania. Subjects were asked to complete an anonymous questionnaire which was structured in five sections. The results obtained from the questionnaires were analyzed separately for sleep bruxism and for awake bruxism. We did not find any statistically significant correlation between awake bruxism or sleep bruxism and age (p = 0.30 and p = 0.37, respectively), sex (p = 0.44 and p = 0.48, respectively), or nationality (p = 0.55 and p = 0.67, respectively). Only a high degree of stress and frustration (p = 0.035 and p = 0.020) was observed in European subjects except for the Romanians and the French, likely related to the difficulties of adapting to the language and lifestyle in Romania. Female sex was statistically significantly associated with an increased level of stress (p = 0.004), duty-related depression (p = 0.006), and duty-related anxiety (p = 0.003). Stress and anxiety can be favorable factors in the appearance of both types of bruxism; however, depression is associated only with awake bruxism.

Sign in / Sign up

Export Citation Format

Share Document